Free tool
FAERS Monitor: Renografin-76
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 010040 or its brand name (Renografin-76, Diatrizoate Meglumine, Diatrizoate Sodium). Reports on generic versions are filed under their own applications.
Reports
158
Serious
144
91% of reports
Hospitalization
122
Death reported
96
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use85
- drug ineffective78
- nausea75
- pain73
- rash72
- confusional state71
- dyspnoea71
- treatment failure71
- wound71
- therapeutic product effect decreased70
- pericarditis69
- psoriatic arthropathy69
- type 2 diabetes mellitus69
- drug hypersensitivity68
- pemphigus68
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 20 |
| 2025 | 59 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,001 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 68 | 728.0 | 608.0 | 48,411 |
| pericarditisSignal | 69 | 549.0 | 459.6 | 37,076 |
| woundSignal | 71 | 339.0 | 285.1 | 23,562 |
| type 2 diabetes mellitusSignal | 69 | 273.4 | 229.0 | 18,447 |
| psoriatic arthropathySignal | 69 | 226.7 | 189.8 | 15,282 |
| therapeutic product effect decreasedSignal | 70 | 208.4 | 174.9 | 14,248 |
| treatment failureSignal | 71 | 114.2 | 96.1 | 7,877 |
| confusional stateSignal | 71 | 58.5 | 49.2 | 3,985 |
| drug hypersensitivitySignal | 68 | 46.8 | 39.1 | 3,029 |
| rashSignal | 72 | 22.0 | 18.5 | 1,452 |
| dyspnoeaSignal | 71 | 16.7 | 14.1 | 1,061 |
| painSignal | 73 | 15.8 | 13.4 | 1,029 |
| off label useSignal | 85 | 12.9 | 11.2 | 963 |
| nauseaSignal | 75 | 12.6 | 10.7 | 821 |
| drug ineffectiveSignal | 78 | 7.9 | 6.7 | 492 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.